The aim of this article is to review the recent trials of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists and positive allosteric modulators (PAMs) on the treatment of cognitive decline in schizophrenia. α7 Nicotinic acetylcholine receptor abnormalities in schizophrenia and clinical implications of α7 nAChR agonists and PAMs are also discussed.. SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Accumulating evidence suggests an involvement of oxidative stress in the pathophysiology of schizophrenia. This offers a hypothesis-derived therapeutic approach to hinder oxidative damage and its clinical sequelae. α-Lipoic acid (ALA) is a powerful natural antioxidant indicated to treat diabetic neuropathy. SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Letter. SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
This research suggests that contrary to popular opinion delaying exposure to cannabis does not appear to reduce the chances of using more of the drug as an older teenager. However, it does suggest that there does not appear to be a strong relationship between developing psychosis as a trigger to stop using cannabis. Again, this won’t come as a surprise to those working with this age group in the mental health or drug field as they will have witnessed this with the young people they encounter as part of their work.
Several studies and meta-analyses have shown that mortality in people with schizophrenia is higher than that in the general population but have used relative measures, such as standardised mortality ratios. We did a systematic review and meta-analysis to estimate years of potential life lost and life expectancy in schizophrenia, which are more direct, absolute measures of increased mortality. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Letter. SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Service data indicates that from a sample of 102 service users 80.4% had their families involved in their care.
In line with offering a combined healthy eating and physical activity programme the service is also piloting the Supporting Health and Promoting Exercise (SHAPE) physical health intervention programme, which uses the expertise of nutritionists, exercise physiologists and health trainers. It is a structured and intensive 12-week course with follow-up over 12 months, which includes a group educational programme and individually tailored exercises sessions.
Throughout the life stages of women with schizophrenia-spectrum disorders (SSD), lower estrogen levels are associated with more severe disease course. At perimenopause in the mid-forties, estrogen levels decline to remain persistently low after menopause. This period is hypothesized to increase relapse risk and reduce antipsychotic effectiveness in preventing relapse.
Commentary on: Chou AIW, Wang Y-C, Lin C-L, et al. Female schizophrenia patients and risk of breast cancer: a population-based cohort study. Schizophrenia Research 2017;188:165–171.
What is already known on this topic
Research into rates of breast cancer in women with schizophrenia shows conflicting results, with reports of increased, decreased and the same risk as the general population. This is despite women with schizophrenia possibly being at increased risk of breast cancer through use of antipsychotic medications, many of which increase prolactin, a hormone involved in cellular differentiation of the mammary glands. This study1 investigated rates of breast cancer in individuals with schizophrenia compared with the general population.. To read the full article, log in using your NHS OpenAthens details.